Escherichia coli isolate MEV, responsible for a bloodstream infection, was resistant to penicillins, cephalosporins, and ertapenem. Molecular and biochemical characterization revealed the production of a novel, chromosome-borne, extended-spectrum AmpC (ESAC) β-lactamase with a Ser-282 duplication and increased carbapenemase activity. This study demonstrates for the first time that chromosome-borne ESAC β-lactamases can contribute to the emergence of ertapenem resistance in E. coli clinical isolates. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Guillon, H., Tande, D., & Mammeri, H. (2011). Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum β-lactamase AmpC. Antimicrobial Agents and Chemotherapy, 55(9), 4443–4446. https://doi.org/10.1128/AAC.01513-10
Mendeley helps you to discover research relevant for your work.